@LittleGunner5@PaulSemple9 The issue is action is needed. With the SP at 5 year lows & a recent news vacuum, there is understandably concern. There are active people targeting Avcata to benefit from the demise so Avacta needs to take hold of the narrative ASAP #AVCT.
@Littleboyblue75@Towlie1981 Alternatively, sell Dx for $15m, pure TX = US investors onboarding, US CFO joins, Partnership release at ACCR in April 2025, runway secured, further US investors onboard due to joining US NasDaq with fund raise. All happening whilst in the midst of a ‘low bid offer’ TO #AVCT
@Littleboyblue75@Towlie1981 So what’s your take on the inclusion of the breast cancer direction? For a company that holds limited funds, taking a new direction into a very saturated & highly regulated market doesn’t make sense… unless.. it’s been directed by a partner/big pharma. Expect news soon.
@Littleboyblue75@Towlie1981 Nah, extended runway through 2025/2026 gives the market confidence on Avacta producing a LD or a partnership. Allowing Avacta to hit new heights.
@nchsongs#AVCT
Still looking to hit the 120p zone which you’ve been saying for half a year now.. the trap door has happened. The ammunition of the shorters and sellers are low. The tide will turn soon. This is easy to see that this has been manipulated massively
@MylesMcNulty@VivekGRamaswamy@TuckerCarlson Congratulations Myles on your portfolio’s best performance recently. I would definitely be interested in hearing more about the possible short term trading ideas. Whilst I appreciate X takes a lot of your time, myself and I know many others greatly appreciate your posts.
@runningprofits A valid and balanced view point. Thanks for your sharing thoughts! I would highly recommend looking into Avacta through Myles McNulty’s investment notes as there is a very strong investment case for the company and our current position. Enjoy the sea swim!